Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 2 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 12275964

    Variant type V CRISPR/Cas effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted Apr 15, 2025 · Expires Apr 10, 2045

    granted
  2. US 12269803

    Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease

    United States Government as represented by the Department of Veterans Affairs · Granted Apr 8, 2025 · Expires Apr 3, 2045

    granted
  3. US 12257288

    Methods of inducing immune tolerance to clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  4. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  5. US 12246057

    Transmembrane stem cell factor (tm-SCF) lipid nanocarriers and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  6. US 12240918

    Bispecific antibodies against plasma kallikrein and factor XII

    Takeda Pharmaceutical Company Limited · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  7. US 12239692

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  8. US 12240914

    Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

    MAB-LEGEND BIOTECH CO., LTD. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  9. US 2025064917

    HVT AIV VECTORS AND USES THEREOF

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Feb 27, 2025 · Expires Feb 22, 2045

    granted
  10. US 12226437

    Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord mesenchymal stem cell expressing IGF1R and method for obtaining multipotent umbilical cord mesenchymal stem cell

    China Medical University · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  11. US 12214023

    Compositions and methods for expressing factor IX

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  12. US 12213996

    Methods of treating optic nerve diseases using neural progenitor cell growth factors

    REGENERATIVE RESEARCH FOUNDATION · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  13. US 12213998

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  14. US 12214031

    Mannheimia haemolytica vector

    The United States of America, as represented by the Secretary of Agriculture · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  15. US 12201721

    Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  16. US 12186375

    Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  17. US 12188039

    Recombinant adeno-associated viral vector for gene delivery

    The Board of Regents of the University of Texas System · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  18. US 12173317

    Use of histone modifiers to reprogram effector T cells

    The Board of Regents of the University of Texas System · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  19. US 12171741

    2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  20. US 12173274

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  21. US 12173307

    Methods for the purification of viral vectors

    BIOVERATIV THERAPEUTICS INC. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  22. US 12161724

    Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens

    JANUX THERAPEUTICS, INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  23. US 12161696

    Methods of treating hemophilic arthropathy using chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  24. US 12156877

    Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor

    The Regents of the University of California · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted